← All trials
NCT05713630
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2024
- Primary completion
- Mar 31, 2025
- Completion date
- Nov 30, 2025
- First posted
- Feb 6, 2023
- Last posted
- Dec 4, 2023
- Enrollment
- 130
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Unity Health TorontoLead sponsor
- Unity Health TorontoOverall official - principal investigator
- Canadian Institutes of Health Research (CIHR)Collaborator
- The Physicians' Services Incorporated FoundationCollaborator
- Applied Health Research CentreCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.